Trial reportEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2012
The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezing.
Trial report in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Effectiveness of Influenza Vaccines in Asthma: A Systematic Review and Meta-Analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017Pooled it
- Safety of live attenuated influenza vaccine (LAIV) in children with moderate to severe asthma.The Journal of allergy and clinical immunology · 2020Trial
- Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study.BMJ (Clinical research ed.) · 2015Trial
- Safety of live attenuated influenza vaccine in atopic children with egg allergy.The Journal of allergy and clinical immunology · 2015Trial
- Trial
- The Live Attenuated Influenza Vaccine in Australia: An Additional Tool for Influenza Prevention.The Medical journal of Australia · 2026Article
- Systematic review of evidence on feasibility of administering intranasal live attenuated influenza vaccine at home.NPJ vaccines · 2025Article
- Allergic Reactions to Vaccines in Children: From Constituents to Specific Vaccines.Biomedicines · 2023Review
- Intradermal vaccination of live attenuated influenza vaccine protects mice against homologous and heterologous influenza challenges.NPJ vaccines · 2021Article
- Immune responses after live attenuated influenza vaccination.Human vaccines & immunotherapeutics · 2018Review
- A multi-site feasibility study to assess fever and wheezing in children after influenza vaccines using text messaging.Vaccine · 2017Observational
- Live attenuated influenza vaccine use and safety in children and adults with asthma.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2017Article
- Development and applications of single-cycle infectious influenza A virus (sciIAV).Virus research · 2016Review
- Article
- A Single Mutation at PB1 Residue 319 Dramatically Increases the Safety of PR8 Live Attenuated Influenza Vaccine in a Murine Model without Compromising Vaccine Efficacy.Journal of virology · 2015Article
- Safety of influenza vaccination in children with allergic diseases.Clinical and experimental vaccine research · 2015Review
- Development of a mouse-adapted live attenuated influenza virus that permits in vivo analysis of enhancements to the safety of live attenuated influenza virus vaccine.Journal of virology · 2015Article
- Vaccination of children with a live-attenuated, intranasal influenza vaccine - analysis and evaluation through a Health Technology Assessment.GMS health technology assessment · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the European Union and Canada, an Ann Arbor strain live attenuated influenza vaccine (LAIV) is approved for use in children aged 2-17 years, including those with mild to moderate asthma or prior wheezing. The safety and efficacy of LAIV versus trivalent inactivated influenza vaccine (TIV) in children with asthma aged 6-17 years have been demonstrated. However, few data are available for children younger than 6 years of age with asthma or prior wheezing. Safety and efficacy data were collected for children aged 2-5 years with asthma or prior wheezing from two randomized, multinational trials of LAIV and TIV (N = 1,940). Wheezing, lower respiratory illness, and hospitalization were not significantly increased among children receiving LAIV compared with TIV. Increased upper respiratory symptoms and irritability were observed among LAIV recipients (p < 0.05). Relative efficacies were consistent with the results observed in the overall study populations, which demonstrated fewer cases of culture-confirmed influenza illness in LAIV compared with TIV recipients. Study results support the safety and efficacy of LAIV among children aged 2-17 years with mild to moderate asthma or a history of wheezing. Data regarding LAIV use are limited among individuals with severe asthma or active wheezing within the 7 days before vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.